Collaboration Forms for Development of Targeted Immunotherapies to Treat Cancer

Collaboration Forms for Development of Targeted Immunotherapies to Treat Cancer (European Pharmaceutical Manufacturer Magazine)

UF startup and UF Innovate | Sid Martin Biotech alumni company Morphogenesis — a Florida-based immunotherapy company — and the Cell and Gene Therapy Group at Karolinska Institutet (KI) in Sweden have announced a collaboration for the development of targeted immunotherapies to treat cancer.

The two-and-a-half-year collaboration will combine Morphogenesis’ gene therapy with the exosome-mediated delivery technology developed by the KI Department of Medicine.

Dr Evren Alici, the KI lead, will use Morphogenesis’ proprietary gene therapy to develop injectable next generation exosome-mediated in vivo cancer therapies. “Exosomes are small vesicles secreted by nearly all cells. Increasingly, exosomes are being recognised as potential therapeutics because they play an important role in intercellular communication,” he explained.

Learn more about Collaboration Forms for Development of Targeted Immunotherapies to Treat Cancer.

X